SCHEMBL16198546

SCHEMBL16198546

CC(C)(C)OC(=O)NCCSc1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.49
BCHE P06276 1/20 0.47
LMNA P02545 4/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
BRD4 O60885 1/20 0.42
POLB P06746 1/20 0.41
PRKAG1 P54619 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16198047 0.83 HSD17B10 (0.53) LMNARECQLRAB9AHSD17B10SMN1; SMN2
SCHEMBL19378074 0.81 BCHE (0.49) IDO1BCHELMNAHSD17B10SMN1; SMN2
SCHEMBL28766639 0.81 CYP1A2 (0.53) BCHELMNARAB9AKDM4EMAPT
SCHEMBL30631822 0.81 CYP1A2 (0.53) BCHELMNARAB9AKDM4EMAPT
SCHEMBL8259877 0.80 BRD4 (0.47) BCHELMNARAB9ASMN1; SMN2KMT2A
SCHEMBL30631837 0.79 BCHE (0.43) BCHELMNARAB9ASMN1; SMN2KMT2A
SCHEMBL4149629 0.79 CACNA1H (0.53) IDO1BCHESMN1; SMN2BRD4TSHR
SCHEMBL17531755 0.79 SMN1; SMN2 (0.51) LMNARECQLRAB9AHSD17B10SMN1; SMN2
SCHEMBL19330681 0.77 CYP1A2 (0.41) BCHELMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL7018125 0.76 IDO1 (0.58) IDO1LMNASMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 US disclosed
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 US disclosed
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 US disclosed
WO-2014176258-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2014-10-30 WO disclosed
WO-2014176258-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS CFTR, SLC11A2, MRPS18A IDO1 2905/4885BCHE 3842/4885LMNA 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.